Cerus makes the INTERCEPT Blood System, which is used to reduce pathogens in donated blood components for transfusion. It last closed at $1.90 on Nov 17, up 2.15% on the day.
Only 1 firm rated CERS in the past 90 days, not enough for a consensus
Average 12-month target
$6.50
▲ 242.1% upside
Based on 1 analyst who set a price target on CERS in the past 90 days. The average target is $6.50, with a high of $6.50 and a low of $6.50, compared with the last close of $1.90.
Low $6.50Avg $6.50High $6.50
Blue marker: last close $1.90
Highest target$6.50
Average target$6.50
Lowest target$6.50
Latest rating changes
Freedom BrokerInitiated
Aug 20Buy$6.50
BTIGUpgrade
May 1Buy$4
Date
Firm
Action
Rating
Price target
Aug 20
Freedom Broker
Initiated
Buy
$6.50
May 1
BTIG
Upgrade
Buy
$4
Loading…
Technical Analysis
CERS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 16% below its 20 day and 23% below its 50 day average. It is 28% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot at $1.89, and the nearest resistance the Pivot R1 at $1.94.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.5%/day
Key levels
$3.4752 week high+82.6%
$2.57100 day average+35.3%
$2.43200 day average+27.9%
$2.3350 day average+22.6%
$2.2020 day average+15.8%
$2.16Swing high (Nov 11)+13.7%
$1.94Pivot R1+2.1%
$1.90Last close
$1.89Pivot−0.5%
$1.85Pivot S1−2.6%
$1.4752 week low−22.6%
Indicators
RSI (14)
36.95
Weak, oversold below 30
Neutral
MACD
-0.12
Below its signal line
Bearish
Stochastic
8.5
Near the bottom of its range
Oversold
ADX (14)
27.9
Trending down
Williams %R
-90.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-118.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−18.8%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Turning down
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityLow, 17.0%/day
Key levels
$3.4752 week high+82.6%
$2.57100 day average+35.3%
$2.43200 day average+27.9%
$2.3350 day average+22.6%
$2.2020 day average+15.8%
$2.16Swing high (Nov 11)+13.7%
$1.94Pivot R1+2.1%
$1.90Last close
$1.89Pivot−0.5%
$1.85Pivot S1−2.6%
$1.4752 week low−22.6%
Indicators
RSI (14)
39.32
Weak, oversold below 30
Neutral
MACD
-0.12
Below its signal line
Bearish
Stochastic
4.2
Near the bottom of its range
Oversold
ADX (14)
16.6
No clear trend
Williams %R
-94.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-145.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.7%
Change over 10 sessions
Bearish
ATR (14)
$0.32
Typical daily range, 17.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CERS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CERS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERS is in one of them and how their past CERS trades turned out.
Cerus is a biomedical products company based in Concord, California. Its main product is the INTERCEPT Blood System, which is designed to reduce bloodborne pathogens in donated blood components intended for transfusion. The system is used to treat platelets and plasma, and a related version produces a fibrinogen complex for treating bleeding linked to fibrinogen deficiency. Cerus sells these products through its own sales force and distributors in several countries, while its red blood cell system remains in development.